Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant in adolescents with major depressive disorder
NCT04951609Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events at 6 weeks, Number of Participants with Adverse Event of Special Interest at 6 weeks and 9 more. Started Sep 2021; status: terminated.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04951609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951609.